2016 年第一季度报告全文 荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2016 年第一季度报告 2016 年 4 月 1 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人付永全、主管会计工作负责人冯丽及会计机构负责人(会计主管 人员)朱迎秋声明：保证季度报告中财务报告的真实、完整。 2 2016 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 1,539.52 | | | 除上述各项之外的其他营业外收入和支出 | -7.41 | | | 减：所得税影响额 | 229.87 | | | 少数股东权益影响额（税后） | ...

Financial Performance - The company's operating revenue for 2015 was ¥541,872,970.24, representing a 31.55% increase compared to ¥411,919,507.99 in 2014[18]. - The net profit attributable to shareholders decreased by 11.08% to ¥50,635,453.88 in 2015 from ¥56,946,829.11 in 2014[18]. - The net profit after deducting non-recurring gains and losses was ¥45,976,761.63, down 15.08% from ¥54,142,899.21 in the previous year[18]. - The net cash flow from operating activities improved significantly to ¥52,973,661.95, a 296.13% increase from -¥27,009,449.76 in 2014[18]. - Total assets increased by 63.54% to ¥1,070,124,752.53 at the end of 2015, compared to ¥654,340,929.71 at the end of 2014[18]. - The net assets attributable to shareholders rose by 97.72% to ¥855,317,558.02 from ¥432,593,035.53 in 2014[18]. - The company reported a basic earnings per share of ¥0.1707, down 18.48% from ¥0.2094 in 2014[18]. - The company's total revenue for the reporting period was ¥541,872,970.24, an increase of ¥129,953,462.25, representing a year-on-year growth of 31.55%[49]. - Operating costs amounted to ¥372,664,253.22, up by ¥103,596,664.08, reflecting a year-on-year increase of 38.50% due to business scale expansion[49]. Investment and Acquisitions - The company acquired 51% of Shanghai Mijian Information Technology Co., Ltd. for 127.5 million yuan, enhancing its market position[37]. - The company's goodwill increased by 126.13 million yuan, a staggering growth of 1,463.78%, resulting from the acquisition of Shanghai Mijian Information Technology Co., Ltd.[38]. - The company invested ¥127,500,000.00 in equity investments during the reporting period, marking a 100% increase compared to the previous year[72]. - The company has committed a total investment of 39,000 million, with 38,385.76 million raised and 26,352.23 million utilized by the end of the reporting period, achieving a utilization rate of 67.5%[80]. - The company has fully repaid bank loans amounting to 5,000 million, achieving a 100% completion rate for this investment[80]. Cash Flow and Liquidity - The net cash inflow from financing activities increased by 323.58% to ¥487,683,821.16, primarily due to funds raised from a private placement of shares[68]. - The net cash outflow from financing activities rose by 160.04% to ¥222,000,810.33, mainly attributed to loan repayments[69]. - The company's cash and cash equivalents increased by 178.08 million yuan, a growth of 128.75%, primarily due to funds raised from a non-public stock offering[37]. - The company's cash and cash equivalents increased by 633.52% to ¥178,370,369.02, reflecting improved liquidity[68]. - The total assets at the end of 2015 amounted to ¥1,070,000,000, with cash and cash equivalents representing 29.57% of total assets, up from 21.14% in 2014[70]. Market Position and Strategy - The company aims to enhance its competitive edge through significant investments in product technology and business model innovation, focusing on differentiated innovation in niche markets[5]. - The company is exploring operational service models to enhance user engagement and brand value, aiming for a leading position in specific segments[5]. - The company is focusing on smart healthcare and health data as key growth areas, with plans to expand into new clinical products[27]. - The company aims to develop a health management O2O platform to integrate various healthcare resources, enhancing service delivery[28]. - The company is positioned to leverage its decade-long experience in regional industry clients to meet the demands of advanced technologies like cloud services and big data[35]. Talent and Human Resources - The company emphasizes the importance of talent retention and has implemented incentive mechanisms to attract and retain high-quality personnel amid increasing industry competition[6]. - The company has implemented a talent development mechanism, with over 90% of executives having training candidates[45]. - The company has a total of 467 employees, with 332 in technical roles, 50 in sales, 17 in finance, and 68 in administration[170]. - The training program achieved a completion rate of over 97% and a course satisfaction rate of 95.6% in 2015[172]. Research and Development - Research and development investment reached ¥31,861,578.82, an increase of ¥5,278,256.85, marking a year-on-year growth of 19.86%[50]. - The number of R&D personnel increased to 175 in 2015, representing 37.47% of the total workforce, slightly down from 38.98% in 2014[65]. - The company launched several new projects in 2015, including a high-concurrency big data platform and a clinical nursing intelligent auxiliary system[64]. - The company is actively working on integrating hardware manufacturers to enhance the sensitivity and accuracy of front-end monitoring devices in health management[35]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 0.35 CNY per 10 shares, totaling 11,250,037.82 CNY for the year 2015, which represents 22.22% of the net profit attributable to ordinary shareholders[107]. - The total distributable profit for the year is 209,943,407.49 CNY, with cash dividends accounting for 100% of the profit distribution[103]. - The company has a history of cash dividends, with 12,240,000.00 CNY distributed in 2014 and 10,880,000.00 CNY in 2013, reflecting a consistent dividend policy[104][105]. - The company’s profit distribution policy allows for cash dividends to be at least 20% of the distributable profit in profitable years, barring special circumstances[106]. Corporate Governance and Compliance - The company has engaged in multiple investor relations activities, indicating a commitment to transparency and communication with stakeholders[100]. - The company has not experienced any significant changes in the feasibility of its fundraising investment projects during the reporting period[82]. - The company has not sold any major assets or equity during the reporting period[83]. - The company has established a plan for employee stock ownership to incentivize staff based on their positions[108]. - The company has confirmed that all funds for the stock issuance are legally owned by the shareholders involved[108].

2015 年第三季度报告全文 荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2015 年第三季度报告 2015 年 10 月 1 2015 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人付永全、主管会计工作负责人冯丽及会计机构负责人(会计主管人员)朱迎秋声明：保证季 度报告中财务报告的真实、完整。 2 □ 是 √ 否 | | 本报告期末 | | 上年度末 | 本报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 度末增减 | | 总资产（元） | | 915,687,971.22 | 654,340,929.71 | 39.94% | | 归属于上市公司普通股股东的股东权益（元） | | 824,742,121.35 | 432,593,035.53 | 90.65% | | 归属于 ...

Financial Performance - Total operating revenue for the first half of 2015 was CNY 195,417,151.80, representing a 30.01% increase compared to CNY 150,314,156.01 in the same period last year[18]. - Net profit attributable to shareholders decreased by 5.76% to CNY 17,680,733.31 from CNY 18,760,891.18 year-on-year[18]. - The basic earnings per share decreased by 5.73% to CNY 0.1300 from CNY 0.1379 in the same period last year[18]. - Operating profit was CNY 15.46 million, up 5.41% year-on-year, while total profit rose to CNY 20.95 million, an increase of 4.33%[32]. - Net profit attributable to shareholders decreased by 5.76% to CNY 17.68 million, primarily due to increased management and financial expenses[28]. - The total comprehensive income for the period was CNY 21,453,022.46[138]. - The total comprehensive income attributable to the parent company was ¥17,674,277.54, compared to ¥18,829,696.46 in the previous period, reflecting a decline of 6.1%[121]. Cash Flow - The net cash flow from operating activities was negative at CNY -95,695,033.08, a decline of 75.73% compared to CNY -54,456,255.36 in the previous year[18]. - The net cash flow from operating activities was -78,511,779.87 CNY, compared to -38,953,487.27 CNY in the previous period, indicating a decline of approximately 101% year-over-year[128]. - Cash and cash equivalents increased significantly to CNY 409,718,054.19 from CNY 117,876,123.93, an increase of 247.5%[114]. - Cash flow from financing activities surged to CNY 373.43 million, a 2,250.52% increase, mainly due to funds raised from a private placement[29]. - Total cash inflow from financing activities reached 473,671,262.32 CNY, significantly up from 42,800,000.00 CNY in the previous period, marking an increase of over 1000%[128]. Assets and Liabilities - Total assets increased by 55.65% to CNY 1,018,513,510.76 from CNY 654,340,929.71 at the end of the previous year[18]. - The total assets of the company reached CNY 1,014,080,664.13, compared to CNY 633,139,803.53 at the beginning of the period, indicating a growth of 60.1%[115]. - The total liabilities decreased to CNY 186,510,463.92 from CNY 198,640,252.59, a reduction of 6.1%[116]. - The company’s total liabilities at the end of the period were CNY 176,013,432.43[136]. - The company’s fixed assets decreased slightly to ¥85,021,152.56 from ¥87,539,220.42, a decline of about 2.9%[111]. Shareholder Information - The company distributed cash dividends of 0.90 RMB per share, totaling 12,240,000 RMB, based on a total share capital of 136,000,000 shares as of December 31, 2014[61]. - The company plans to increase its share capital by 100% through a capital reserve transfer, proposing to issue 160,714,826 new shares to shareholders at a ratio of 10 shares for every 10 shares held[63]. - The total amount of capital contributions from shareholders was CNY 383,857,626.81[138]. - The total number of shares after the issuance increased to 160,714,826 shares, with 59,356,467 shares subject to restrictions and 76,643,533 shares unrestricted[94]. - The company has 6,699 shareholders at the end of the reporting period, with the largest shareholders, Fu Yanjie and Cui Wantao, each holding 28.87% of the shares[97]. Research and Development - Research and development investment increased by 5.48% to CNY 12.09 million[29]. - The company focused on R&D in smart application cloud, livelihood service cloud, and intelligent analysis cloud during the first half of 2015[38]. - The company is focusing on high-growth sectors such as smart healthcare and smart cities, developing integrated services and intelligent analysis platforms[37]. - The renal comprehensive information management system achieved significant market breakthroughs due to enhanced product optimization and increased marketing efforts[39]. - The smart medical application products, including the hospital nursing resource planning platform, received high praise from clients after partial implementation at the Fuwai Cardiovascular Hospital[39]. Corporate Strategy - The company plans to enhance its competitive edge through differentiated innovation in product technology and exploring operational service models[23]. - The company is implementing a strategy focused on innovation in smart medical and smart city sectors, aiming to create a closed-loop of products and services[42]. - The company is advancing its smart city applications by investing in deep applications of social security and medical insurance data[39]. - The company is actively recruiting key technology talents and enhancing employee training to support continuous innovation and management stability[44]. - The company plans to continue focusing on expanding its market presence and enhancing product offerings in the upcoming quarters[132]. Governance and Compliance - The financial report for the first half of 2015 was approved by the board of directors on August 25, 2015[150]. - The company has no significant contracts, leasing, or entrusted cash asset management during the reporting period[76][82][84]. - The company has no violations regarding external guarantees during the reporting period[81]. - The company’s board of directors and senior management did not change during the reporting period[106]. - The company reported no changes in the controlling shareholder or actual controller during the reporting period[101].

荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2015 年第一季度报告 2015 年第一季度报告全文 2015 年 4 月 1 2015 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人付永全、主管会计工作负责人冯丽及会计机构负责人(会计主管 人员)朱迎秋声明：保证季度报告中财务报告的真实、完整。 2 2015 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 78,061,852.87 | 64,508,854.25 | 21.01% | | 归属于上市公司普通股股东的净利润 | 5,37 ...

Financial Performance - The company's operating revenue for 2014 was CNY 411,919,507.99, representing a 9.67% increase compared to CNY 375,586,047.92 in 2013[23]. - The net profit attributable to shareholders for 2014 was CNY 56,946,829.11, which is a 7.02% increase from CNY 53,211,289.80 in 2013[23]. - The total assets at the end of 2014 reached CNY 654,340,929.71, marking a 15.69% increase from CNY 565,615,807.03 at the end of 2013[23]. - The company's total liabilities increased by 24.24% to CNY 211,758,370.86 in 2014, up from CNY 170,449,151.64 in 2013[23]. - The weighted average return on equity for 2014 was 13.87%, a decrease of 0.71 percentage points from 14.58% in 2013[23]. - The basic earnings per share for 2014 was CNY 0.4187, which is a 7.00% increase from CNY 0.3913 in 2013[23]. - The company's equity attributable to shareholders increased by 11.92% to CNY 432,593,035.53 at the end of 2014, compared to CNY 386,504,020.87 at the end of 2013[23]. Cash Flow and Investments - The net cash flow from operating activities improved significantly, with a net outflow of CNY 27,009,449.76 in 2014, compared to a net outflow of CNY 113,996,084.75 in 2013, reflecting a 76.31% improvement[23]. - Operating cash inflow totaled CNY 393,243,372.51 in 2014, reflecting a year-over-year increase of 21.56%[59]. - The net cash flow from operating activities increased by 86.99 million yuan, a year-on-year growth of 76.31%, primarily due to increased cash received from sales and reduced cash paid for goods and services[61]. - Cash inflow from investing activities decreased by 655,300 yuan, a decline of 95.77%, mainly due to reduced net cash inflow from consolidated subsidiaries[62]. - Cash outflow from investing activities increased by 9,919,500 yuan, a year-on-year increase of 37.67%, primarily due to property acquisitions[62]. - The net cash flow from financing activities decreased by 64,888,500 yuan, a year-on-year decline of 68.56%, mainly due to increased repayment of short-term loans[62]. Research and Development - Research and development expenses reached ¥26,583,321.97, an increase of ¥670,446.24, with a year-on-year growth of 2.59%[49]. - The company invested CNY 26,583,321.97 in R&D in 2014, representing 6.45% of its operating revenue, a decrease from 6.90% in 2013[58]. - The company has effectively reduced research and development costs by leveraging existing experience and government support in its projects[91][92]. Market Expansion and Strategy - The company is actively expanding into international markets, particularly the U.S., through overseas acquisitions and developing a sales and service network across major regions in China[41]. - Significant investments in technology innovation and product development were made, particularly in healthcare applications and big data analytics, with a focus on IoT data collection and analysis[42]. - The company is focusing on the development of smart cities, with significant government support and a coordinated approach among various ministries[100]. - The healthcare IT market is projected to reach CNY 33.99 billion by 2016, with a compound annual growth rate of 18.40% from 2011 to 2016[102]. - The company aims to become a leading application and operation service provider in the livelihood sector, focusing on "smart, health, and safety" in 2015[106]. Risk Management and Internal Control - The company is enhancing its internal control systems to improve risk management capabilities, focusing on a risk-oriented approach and internal audits[47]. - The company is facing market competition risks as new entrants increase, necessitating timely technological and business model innovations to maintain competitiveness[30]. Shareholder and Dividend Policy - The company has established a cash dividend policy, aiming to distribute at least 20% of the distributable profits as cash dividends annually, barring special circumstances[112][115]. - The company plans to distribute a cash dividend of 0.90 RMB per 10 shares, totaling 12,240,000 RMB, based on a total share capital of 136,000,000 shares as of December 31, 2014[120]. - The cash dividend represents 21.49% of the net profit attributable to the company's ordinary shareholders, which was 56,946,829.11 RMB for the year 2014[123]. - The company has maintained a cash dividend payout ratio of over 20% for the past three years, with 20.45% in 2013 and 20.46% in 2012[123]. Corporate Governance - The company has established and executed an insider information management system to protect investors' rights[124]. - The company has a diverse board with members holding various positions in other organizations, enhancing its governance structure[194][195][196][197]. - The board includes independent directors with significant academic and professional backgrounds, contributing to strategic decision-making[196][197]. - The company is focused on maintaining a strong leadership team with a mix of experienced professionals and independent directors[194][195]. Acquisitions and Investments - In September 2014, the company acquired industrial land and buildings from Shenyang Yitian Biopharmaceutical Co., Ltd. for 28.09 million RMB[134]. - The acquisition was aimed at supporting the company's rapid development and increasing personnel needs[134]. - The company reported an investment loss of ¥1,440,395.08 from its 50.87% stake in Xiangyun Technology Company[79]. - The company plans to issue up to 24.57 million shares at a price of CNY 15.87 per share in a non-public offering, which has been approved by the board[146]. Shareholder Structure - The total number of shareholders at the end of the reporting period was 6,418, a decrease from 7,582 five trading days prior to the report date[179]. - Major shareholders include Fu Yanjie and Cui Wantao, each holding 28.87% of shares, totaling 39,266,714 shares, both of which are pledged[179]. - The company has committed to a lock-up period for shares held by major shareholders until February 16, 2015[188].

Financial Performance - Total revenue for the reporting period was ¥63,350,551.55, down 5.82% year-over-year[9]. - Net profit attributable to shareholders was ¥2,564,989.42, a decline of 25.37% compared to the same period last year[9]. - Basic earnings per share were ¥0.0189, down 25.30% year-over-year[9]. - The weighted average return on equity decreased to 0.66%, down 0.31 percentage points from the previous year[9]. - The company reported a total operating cost of ¥196,603,073.90 for the year-to-date period, a decrease from ¥200,408,821.86[73]. - Year-to-date net profit was ¥20,797,886.24, compared to ¥23,778,540.85, indicating a decrease of approximately 12.5%[74]. - The company's total revenue for Q3 2014 was ¥59,963,459.55, an increase from ¥53,166,792.07 in the previous period[69]. - Net profit for Q3 2014 was ¥5,149,562.58, down from ¥5,729,300.36, indicating a decrease of about 10.1% year-over-year[69]. Assets and Liabilities - Total assets at the end of the reporting period were ¥523,954,659.29, a decrease of 7.37% compared to the previous year[9]. - Cash and cash equivalents decreased by 76.03%, from 170,129,083.93 to 40,779,894.86, primarily due to increased bank loan repayments and cash outflows from operating activities[24]. - Accounts receivable increased by 261.31%, from 794,000.00 to 2,868,796.22, mainly due to an increase in customers using bank acceptance bills for settlement[24]. - Inventory increased by 56.34%, from 33,455,933.68 to 52,306,556.21, attributed to an increase in unfinished projects at the end of the period[24]. - Total liabilities decreased to ¥118,735,579.20 from ¥170,449,151.64, indicating a significant reduction in financial obligations[61]. Strategic Initiatives - The company is focusing on expanding into smart healthcare and smart city sectors as part of its strategic transformation[12]. - The company plans to enhance R&D efforts to quickly launch new products that meet market demands[12]. - The company is actively pursuing technology R&D, market expansion, and mergers and acquisitions to drive business transformation[27]. - Significant projects include the successful signing of the "Digital Hospital Construction" project with Guiyang Fourth People's Hospital and the establishment of a joint R&D center with Fuwai Hospital[27]. - The company is developing a comprehensive health service platform to address the rapid growth of health big data and improve grassroots medical service levels[30]. Market Presence and Competition - The company is actively expanding its market presence beyond Northeast China to mitigate regional concentration risks[14]. - The company faces intensified competition in the IT service sector, which may impact future profitability and operational performance[38]. - The overall business performance remains stable despite increased operational costs and intensified market competition[27]. Financial Management - The management is committed to strengthening accounts receivable management to address potential cash flow impacts[15]. - The company received tax refunds of 4,935,860.45, a 162.86% increase compared to the previous year, due to increased VAT refunds[26]. - Financial expenses rose by 222.97%, from 888,499.73 to 2,869,628.31, mainly due to increased interest expenses[25]. - The company is focused on improving accounts receivable management to address potential cash flow impacts from increased receivables[40]. Shareholder Information - Total number of shareholders at the end of the reporting period is 6,635[18]. - The top two shareholders, Fu Yanjie and Cui Wantao, each hold 28.87% of the shares, totaling 39,266,714 shares, which are pledged[18]. - The total number of restricted shares at the end of the period is 79,012,400, with no new restricted shares added during the reporting period[21]. Cash Flow and Investments - Cash inflow from sales of goods and services reached ¥190,271,078.45, an increase from ¥167,208,810.77 in the previous period[79]. - Total cash inflow from operating activities amounted to ¥206,030,012.98, compared to ¥178,039,223.27 in the prior period, reflecting a growth of approximately 15%[80]. - The company has achieved a cumulative investment of CNY 10,759.83 million against a committed investment of CNY 12,870.16 million[46]. - The company distributed a cash dividend of CNY 0.80 per share, totaling CNY 10.88 million, based on a total share capital of 136 million shares as of December 31, 2013[53].

Financial Performance - Total revenue for the reporting period was ¥150,314,156.01, a decrease of 3.64% compared to ¥155,992,877.72 in the same period last year[18]. - Net profit attributable to ordinary shareholders was ¥18,760,891.18, down 7.98% from ¥20,387,281.07 year-on-year[18]. - Basic earnings per share decreased by 8.01% to ¥0.1379 from ¥0.1499 in the same period last year[18]. - The weighted average return on net assets decreased to 4.74%, down 1.02 percentage points from 5.76% in the previous year[18]. - The company achieved operating revenue of 150.31 million yuan, a decrease of 3.64% compared to the same period last year[28]. - Net profit attributable to shareholders was 18.76 million yuan, down 7.98% year-on-year[28]. - The company reported a net profit of ¥18,760,891.18 for the current period, contributing to an increase in retained earnings[130]. - The total equity attributable to the parent company at the end of the period was ¥402,888,867.58, reflecting a slight increase from the previous year[131]. Cash Flow and Liquidity - Net cash flow from operating activities improved to -¥54,456,255.36, a 66.84% increase compared to -¥164,203,923.66 in the previous year[18]. - The cash inflow from operating activities was ¥151,795,166.52, an increase from ¥135,122,915.15 in the previous period, suggesting better operational performance[128]. - The net cash flow from operating activities was -¥38,953,487.27, an improvement from -¥151,154,899.84 in the previous period, indicating a significant reduction in cash outflow[128]. - Cash and cash equivalents decreased from 170,129,083.93 RMB to 90,684,309.77 RMB, representing a decline of about 46.6%[109]. - The total cash and cash equivalents at the end of the period stood at ¥79,823,385.38, down from ¥103,451,376.94 at the end of the previous period[129]. Investment and R&D - Research and development investment increased by 7.95% to 11.46 million yuan[29]. - The company plans to enhance research and development efforts in the livelihood sector to meet evolving customer needs and explore new profit growth points[24]. - The company is continuing its unified development platform project based on J2EE 5 architecture, aiming for productization[41]. - The organic solar cell research project focuses on high-performance inverted molecular solar cell technology as part of the company's foundational research investment[41]. - The company has made significant progress in developing medical big data platforms, particularly in personal health management[46]. Market Strategy and Business Development - The company plans to focus on innovation and service improvement to address the slowdown in client demand due to macroeconomic conditions[24]. - The strategic shift towards smart healthcare and smart city projects is aimed at expanding the market and mitigating operational risks associated with business structure adjustments[24]. - The company focused on smart healthcare and smart city projects, achieving significant breakthroughs in market expansion[28]. - The company plans to continue its strategic focus on mergers and acquisitions to expand its market reach beyond the northeastern region[28]. - The company has established a technology competitiveness in smart city solutions, including intelligent video analysis and big data analytics[45]. Financial Position and Assets - Total assets at the end of the reporting period were ¥530,931,075.44, a decline of 6.13% from ¥565,615,807.03 at the end of the previous year[18]. - The total amount of raised funds is 188.87 million RMB, with 12.53 million RMB already invested during the reporting period[50]. - The cumulative amount of raised funds invested to date is 125.29 million RMB[50]. - The company reported a total of 436,947,788.06 RMB in current assets at the end of the reporting period, down from 476,077,459.34 RMB at the beginning of the period, indicating a decrease of approximately 8.6%[109]. - The total equity at the end of the current period is CNY 390,834,195.11, up from CNY 343,184,726.17 at the end of the previous year, indicating a growth of approximately 13.9%[138]. Shareholder Information - The total number of shareholders at the end of the reporting period is 8,986[95]. - The company has 136,000,000 shares in total, with 79,012,400 shares (58.10%) under limited sale conditions and 56,987,600 shares (41.90%) under unrestricted sale conditions[95]. - The company distributed a cash dividend of 0.80 RMB per share, totaling 10.88 million RMB, based on a total share capital of 136 million shares as of December 31, 2013[63]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[66]. Compliance and Governance - The company adheres to the Chinese Accounting Standards, ensuring that its financial statements accurately reflect its financial position and operating results as of June 30, 2014[148]. - The company has a structured governance framework with a board of directors consisting of 9 members, including 3 independent directors, and a supervisory board with 3 members[146]. - There were no significant litigation or arbitration matters during the reporting period[69]. - The company did not engage in any related party transactions during the reporting period[74]. Accounting Policies and Practices - The company’s accounting policies include specific methods for handling mergers and acquisitions, ensuring compliance with relevant accounting standards[153][155]. - Cash and cash equivalents are defined as cash on hand and deposits that are readily available for payment, with cash equivalents typically maturing within three months from the date of purchase[160]. - The company applies an aging analysis method for receivables, with specific percentages for impairment provisions based on aging categories, such as 2% for within 1 year and 100% for over 5 years[177]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[180].

2014 年 04 月 2014 年第一季度报告全文 荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2014 年第一季度报告 1 2014 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人付永全、主管会计工作负责人冯丽及会计机构负责人(会计主管 人员)朱迎秋声明：保证季度报告中财务报告的真实、完整。 2 2014 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业总收入（元） | 64,508,854.25 | 46,997,295.35 | 37.26% | | 归属于公司普通股 ...

Financial Performance - The company's operating revenue for 2013 was CNY 375,586,047.92, representing a 12.20% increase compared to CNY 334,734,262.56 in 2012[26] - The net profit attributable to shareholders of the listed company was CNY 53,211,289.80, an increase of 6.72% from CNY 49,862,341.25 in the previous year[26] - The total assets at the end of 2013 amounted to CNY 565,615,807.03, reflecting an 11.51% increase from CNY 507,253,746.40 at the end of 2012[26] - The company's cash flow from operating activities was negative at CNY -113,996,084.75, a significant decline of 471.32% compared to CNY 30,700,578.99 in 2012[26] - The basic earnings per share for 2013 was CNY 0.3913, a 2.27% increase from CNY 0.3826 in 2012[26] - The weighted average return on equity decreased to 14.58%, down by 2.07 percentage points from 16.65% in the previous year[26] - The total liabilities at the end of 2013 were CNY 170,449,151.64, which is a 5.05% increase from CNY 162,248,506.90 at the end of 2012[26] - The company's asset-liability ratio improved to 30.14%, a decrease of 1.85 percentage points from 31.99% in 2012[26] - The net profit after deducting non-recurring gains and losses was CNY 47,168,700.22, up 4.53% from CNY 45,122,553.86 in 2012[26] Investment and R&D - The company invested CNY 25,912,875.73 in R&D in 2013, representing 6.90% of its operating revenue[61] - The R&D investment increased from CNY 16,566,993.48 in 2012 to CNY 25,912,875.73 in 2013, showing a growth rate of approximately 56.4%[61] - Significant investments in technology innovation and product development have been made, focusing on smart city and smart healthcare solutions, with new systems and platforms being developed[44] - The company completed the development of multiple new products, including a mobile medical information management system and a social security risk supervision platform[60] - The company is in the research phase for a low-power wearable ECG measurement device, indicating a focus on innovative health technology[61] Market Expansion and Strategy - The company is actively expanding into international markets, particularly in the Northwest, North China, and Southwest regions, while also pursuing overseas acquisitions to enhance its presence in the U.S. market[43] - The company aims to enhance its core technological competitiveness in the smart city sector, focusing on video, image analysis, GIS, and expert decision systems[103] - The company is actively pursuing market expansion through new product development and strategic partnerships in the healthcare sector[60] - The company plans to establish multiple customer joint innovation bases to develop leading domestic solutions in smart healthcare and smart cities[103] Financial Management and Structure - The company has optimized its business structure by integrating IoT, cloud computing, and mobile internet technologies into existing products, enhancing profitability[47] - The company has emphasized strengthening internal control systems to ensure effective risk management and compliance[50] - The company has committed to investing in projects totaling approximately $12.87 million, with a significant portion of raised funds already allocated[83] - The company has utilized 600.00 million of the raised funds to permanently supplement working capital, which is limited to operations related to its main business[87] Shareholder and Equity Information - The total number of shares increased from 68,000,000 to 136,000,000 due to a capital reserve conversion of 10 shares for every 10 shares held[162] - The proportion of limited sale shares decreased from 75.00% to 58.10% after the release of certain pre-IPO restricted shares[161] - The number of unrestricted shares increased from 17,000,000 to 56,980,648, representing 41.90% of the total shares[161] - The company had a total of 9,414 shareholders at the end of the reporting period, an increase from 9,179 in the previous period[170] - Major shareholders, Fu Yanjie and Cui Wantao, each hold 28.87% of the shares, totaling 39,266,714 shares[170] Risk Factors - The company faces risks related to market competition, seasonal fluctuations, and human resource challenges, which could impact its operational performance[36][37][38] - Fixed asset depreciation is expected to increase due to ongoing investment projects, potentially leading to a decline in profits[39] Corporate Governance - The company has established an insider information management system to protect investors' rights and ensure fair information disclosure[121] - The company has not faced any penalties from securities regulatory authorities for its directors, supervisors, or senior management[195] - The company’s board of directors includes independent members with academic and professional backgrounds in economics and finance[190] Compensation and Remuneration - Total compensation for the company's directors and senior management during the reporting period amounted to 358 million[198] - The chairman and general manager, Fu Yongquan, received a total compensation of 74 million[198] - The financial director, Feng Li, received a total compensation of 52 million[198] - The sales director, Yin Chunfu, received a total compensation of 55 million[198]